Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00244244 · ClinicalTrials.gov registry record · Phase 2
A Multicenter, Dose Ranging Safety and Pharmacokinetics Study of Arimoclomol in ALS
A Phase 2 study, sponsored by CytRx.
- Completed
- Registry status
- Phase 2
- Development phase
- 80
- Enrollment target
NCT00244244 is a Phase 2 study that has completed, run by CytRx. The registered enrollment target is 80 participants.
The verdict
NCT00244244, a Phase 2 study, has completed, sponsored by CytRx.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 80 participants
- Enrollment target
Study Summary
The primary purpose of this study is to evaluate the safety and tolerability of arimoclomol in ALS patients following 90 days of dosing. In addition, the amount of arimoclomol in blood and cerebrospinal fluid will be measured.
Interventions
- DRUG arimoclomol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2005-10 |
| Est. Completion | 2007-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00244244
The ClinicalTrials.gov registry entry for NCT00244244 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CytRx, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which arimoclomol is the first listed.
NCT00244244 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00244244 about?
NCT00244244 is a clinical study titled "A Multicenter, Dose Ranging Safety and Pharmacokinetics Study of Arimoclomol in ALS". The primary purpose of this study is to evaluate the safety and tolerability of arimoclomol in ALS patients following 90 days of dosing. In addition, the amount of arimoclomol in blood and cerebrospinal fluid will be measured.
What is the current status of trial NCT00244244?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 80 participants. The study started on 2005-10. Estimated completion is 2007-01.
What interventions are being tested in trial NCT00244244?
The interventions under investigation include: arimoclomol (DRUG).
Who is sponsoring clinical trial NCT00244244?
This trial is sponsored by CytRx, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.